On food additives yes, but vaccines that's a whole different story. |
I'm not surprised. He tells the truth. The big boys won't want that. |
This is a key area on the chart here. A close below 21p will see price test 18-19p area. People are getting bored here. |
There seems to be more push back in Congress about RFK Jnr.
All they need are 3 Republican's to vote Nay. |
This time in 2028 Rodney.... |
STT you really do seem to spread your bile on a lot of bb’s….. chill mate, don’t let it get to you |
Sounds a bit desperate to me |
 Interesting an email I received this morning from the horses mouth.Looks like Mo's on a mission to drum up business.
Dear ,
We are pleased to share that our colleagues at hVIVO have been featured in Nature Communications with a peer-reviewed paper titled “SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections”.
;
This publication builds on the groundbreaking insights from the world’s first COVID-19 characterisation trial we conducted in 2021 in collaboration with Imperial College London, the UK Vaccine Taskforce, the Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust.
Read the full article here: Nature Communications
The study identified key biomarkers in the blood activated, not only in SARS-CoV-2 infection but also in other respiratory viruses, that can identify and distinguish between the early and late phases of infection. These biomarkers could provide a basis for advancements in infection diagnosis and management in early and late-stage infections.
Human challenge trials allow researchers to observe infection progression, particularly in the early stages, in detail that would not be possible with a traditional field study. Excitingly, the early-stage marker was observable sometimes even before PCR testing confirmed the presence of the virus, suggesting future clinical utility in inferring the infectiousness of a patient early in the infection time-course as well as a potential role in helping stratify patients for antiviral therapy.
We are delighted to see that hVIVO’s impactful contributions during the COVID pandemic continue to enhance understanding of the immune response to SARS-CoV-2 infection and other respiratory viruses.
If you’d like to discuss how our expertise in human challenge trials could help support the clinical development of your drug candidates, or to learn more on our expanded laboratory and site study services, then please reach out at BD@hvivo.com.
Kind regards,̴3;
Yamin 'Mo' Khan
CEO |
You're now repeating the same dirge, so in the bin for you. I'm all for different opinions, but yours has got a bit excessive now... |
Chica
"How low will the market take the share price"
I think to around 10p
The company newsflow has been as expected.
Oh look, Nexn thread busy, HVO quiet. Looks like 1gw and his mates have moved back to ramping nexn, another with a highly questionable business model (their peers refuse to use the same business model) and several different name changes. The share price there has crashed multiple times over the years.
How many multiple ids do you have 1gw? |
ali47fish,
I would say not really new, but news.
However if this biomarker is just out there, not sure of the significance to HVO, if we had some sort of discovery ownership then there might be a value, however I suspect because of the consortium any value in this new biomarker won't be HVO's.
So good news story but no particular relevance to Challenge studies, more to diagnostic companies who can use this new biomarker for tests. |
It's not news,it's filler...
Bottom line for Hvivo right now is how they are going to beat 2024 revenue of £62 million in 2025.
And
If they don't how low will the market take the share price |
Yes. COVID/ respiratory diseases are a very popular area of drug development hence why the RSV challenge model is popular with clients. At £10 million + a pop for a challenge study this will bring in plenty of cash going forward. |
is this significant and new though |
A new peer review paper has been published in Nature Communications titled "SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections". This publication builds on the groundbreaking insights from the world's first COVID-19 characterisation trial we conducted in 2021. Please see link to RNS available here: https://www.londonstockexchange.com/news-article/HVO/covid-19-study-published-in-nature-communications/16807788 The study identified key biomarkers in the blood activated, not only in SARS-CoV-2 infection but also in other respiratory viruses, that can identify and distinguish between the early and late phases of infection. These biomarkers could provide a basis for advancements in infection diagnosis and management in early and late-stage infections. Human challenge trials allow researchers to observe infection progression, particularly in the early stages, in detail that would not be possible with a traditional field study. We are delighted to see that hVIVO's impactful contributions during the COVID pandemic continue to enhance understanding of the immune response to SARS-CoV-2 infection and other respiratory viruses. Don't hesitate to contact me should you have any |
COVID/respiratory diseases challenge agent should prove popular with clients |
Could be a woman |
Funny I had the impression Pogue was an elderly bloke by his posting here.
I'd have thought his so called colleagues (who apparently he was out on the lash with)would have been filtered🤔28527; |
Pogue filtered. Pathetic when someone has blinkers on and won't see alternative views. |
ltbh often quoted but incorrectly.
Actually means: long term buy and hope.
Because very very few people have the knowledge, analysis and resources of Buffett. |
as long as it takes no rush at all |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
